Clostridium difficile Infection

Research output: Research - peer-reviewReview article

Abstract

Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care–associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment.

LanguageEnglish (US)
Pages489-495
Number of pages7
JournalInfectious Disease Clinics of North America
Volume31
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Clostridium Infections
Clostridium difficile
Delivery of Health Care
Therapeutics
Centers for Medicare and Medicaid Services (U.S.)
Centers for Disease Control and Prevention (U.S.)
Motivation
Economics
Anti-Bacterial Agents

Keywords

  • Centers for Disease Control and Prevention
  • Clostridium difficile
  • Intensive care units
  • White blood cell

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Clostridium difficile Infection. / Bartlett, John G.

In: Infectious Disease Clinics of North America, Vol. 31, No. 3, 01.09.2017, p. 489-495.

Research output: Research - peer-reviewReview article

@article{ebad30d1ad9243578a90ff9f5beda76a,
title = "Clostridium difficile Infection",
abstract = "Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care–associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment.",
keywords = "Centers for Disease Control and Prevention, Clostridium difficile, Intensive care units, White blood cell",
author = "Bartlett, {John G.}",
year = "2017",
month = "9",
doi = "10.1016/j.idc.2017.05.012",
volume = "31",
pages = "489--495",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Clostridium difficile Infection

AU - Bartlett,John G.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care–associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment.

AB - Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care–associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment.

KW - Centers for Disease Control and Prevention

KW - Clostridium difficile

KW - Intensive care units

KW - White blood cell

UR - http://www.scopus.com/inward/record.url?scp=85026851352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026851352&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2017.05.012

DO - 10.1016/j.idc.2017.05.012

M3 - Review article

VL - 31

SP - 489

EP - 495

JO - Infectious Disease Clinics of North America

T2 - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 3

ER -